Oligodendroglioma (OG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Oligodendroglioma (OG) Market Outlook

Thelansis’s “Oligodendroglioma (OG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oligodendroglioma (OG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Oligodendroglioma (OG) Overview

Oligodendroglioma (OG) is a rare type of glial tumor primarily found in the white matter of the cerebral hemisphere, especially in the supratentorial region. This tumor is characterized by a highly cellular lesion that diffusely infiltrates the periphery and consists of evenly-spaced monomorphic cells with the oligodendroglial phenotype. The cells are uniformly round to oval with round nuclei, delicate chromatin and small nucleoli. The most common clinical presentation is seizures. There are three types of OG: Grade 2 oligodendroglioma (low grade), Grade 2 oligoastrocytoma (low grade), Grade 3 anaplastic oligodendroglioma (high grade), and Grade 3 anaplastic oligoastrocytoma (high grade). The cause of OG is still unknown, but certain risk factors such as age, exposure to ionizing radiation, and family history of glioma can increase the risk of developing this tumor. Treatment of OG is multifactorial and includes surgical, chemotherapy, and radiation therapy methods. Low-grade OG (WHO Grade II), which has 1p/19q deletion and IDHmt, have a better prognosis than other astrocytomas without these genetic markers. OGs have a median survival time of 10-12 years and 5- years progression-free and overall survival rates of 51-83%. Overall and 5-year survival rates decrease with higher-grade anaplastic OG, with a median survival time of 3.5 years in WHO Grade III tumors. Diffuse astrocytoma is the primary differential diagnosis on imaging and is difficult to distinguish from OG. Complications from OGs may include seizures, postsurgical complications, thromboembolic events, chemotherapy side effects, and long-term effects of radiation, such as cognitive deficits, gait abnormalities, or radiation necrosis. Residual or recurrent OGs can also undergo malignant degeneration over time.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Oligodendroglioma (OG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034